MGX · Metagenomi Therapeutics, Inc.
Market Cap
$44.95M
Shares
37.78M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$25.21M
-51.8%
FY2025
Net Income
-$87.87M
-12.6%
FY2025
Operating Margin
-380.85%
-210.8pp
FY2025
Diluted EPS
-$2.36
0%
FY2025
Operating Cash Flow
-$88.89M
+18.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $22.33M | $25.21M | $52.3M | $44.76M | |
| $88.6M | $94.43M | $109.18M | $94.4M | |
| $25.53M | $26.79M | $32.02M | $28.85M | |
| $114.13M | $121.22M | $141.2M | $123.25M | |
| -$100.57M | -$96.01M | -$88.9M | -$78.49M | |
| — | -380.85% | -170% | -175.38% | |
| $6.89M | $9.47M | $14.72M | $15.47M | |
| $6.91M | $8.09M | $5.33M | $18.26M | |
| -$93.65M | -$87.93M | -$83.57M | -$60.23M | |
| -$190K | -$58K | -$5.51M | $8.03M | |
| -$93.46M | -$87.87M | -$78.06M | -$68.26M | |
| — | -348.54% | -149.26% | -152.5% | |
| -$93.96M | -$88.32M | -$77.25M | -$68.08M | |
| USD/shares | -$2.48 | -$2.36 | -$2.36 | -$20.05 |
| USD/shares | -$2.48 | -$2.36 | -$2.36 | -$20.05 |
| shares | — | 37.25M | 33.03M | 3.4M |
| shares | — | 37.25M | 33.03M | 3.4M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.28×
EV/EBIT
—
P/E (TTM)
—
Peer median 5.74×
Peer medians compare against the 267 similar-size Biotechnology companies (of 514 listed).
Key facts
CIK
1785279
CUSIP
59102M104
13F (30d)
40 filings
40 filers
Visit website
Investor relations